IL1B and myeloid sarcoma: Following treatment with PC, LF, MF, HF, and MS, the serum levels of TNF-α and IL-1β were significantly reduced (p < 0.05), with PC, LF, MF, and HF demonstrating more pronounced therapeutic effects.